Biologic Agents in the Treatment of Psoriasis

Author(s): Fabrizio Guarneri, Claudio Guarneri, Biagio Guarneri.

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 1 , Issue 3 , 2007

Become EABM
Become Reviewer

Abstract:

Psoriasis is a cutaneous inflammatory disease, which affects 1-5% of general population and can have, particularly in its moderate-severe forms, a significant impact on the quality of life of patients. Although the etiopathogenesis of psoriasis is not yet fully understood, it has been demonstrated that the disease is the result of a complex interaction of genetic, endogenous and environmental factors, where the immune system has a pivotal role. For this reason, the immune system is the main target of many treatments for psoriasis. The most recent evolution in this field are the so-called biologic agents, custom-designed biomolecules obtained by bioengineering. This review summarizes the currently available data about efficacy, safety and undesired effects of five patented biologics officially approved for the treatment of moderate-to-severe psoriasis: adalimumab, alefacept, efalizumab, etanercept and infliximab. Some patent applications concerning possible future evolutions of the above biologics are also discussed.

Keywords: Psoriasis, therapy, biologics, efficacy, safety, side effects, adalimumab, alefacept, efalizumab, etanercept

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 1
ISSUE: 3
Year: 2007
Page: [193 - 217]
Pages: 25
DOI: 10.2174/187221307782418919
Price: $58

Article Metrics

PDF: 3